WCN-DCVA Pitch

17 May 2021

In 2020 DCVA partner WCN (Dutch Network for Cardiovascular Research) published the results of LoDoCo2. This Drug Rediscovery Project showed a major protective effect of the ancient anti-inflammatory drug colchicine in patients with chronic coronary disease. LoDoCo2 is the first trial fully operated by (and through) our investigator network after selection at the first WCN-pitch. It shows how WCN can contribute to the ambition of the DCVA to lower the cardiovascular disease burden in The Netherlands.

Over the past decades WCN has contributed substantially in industry initiated trials that changed the guidelines; the core business of the network. In LoDoCo2 the commitment of experienced investigators and site teams combined with the operational and scientific expertise of the WCN board and staff has proven to be a powerful setup for investigator initated clinical trials also.

DCVA and WCN now invite the Alliance partners in the next collaborative Pitch. The event has been postponed due to the pandemic, but will now take place May 17th, 2021 in a blended invitational setting.

What’s the purpose of this Pitch? We challenge investigators and funders within the DCVA to collaborate. Over the past years a number of passionate investigators have approached our network for future trials aimed to contribute to the health of our patients. In the WCN-DCVA Pitch WCN offers her support and initial funding to the project, chosen in two rounds by the DCVA partners and WCN members, hoping for further substantial collaboration with other DCVA funding partners.

For more information or to apply please contact Astrid Schut (WCN) via a.schut@wcn.life